The life sciences company reported a 102% increase in revenue and improved gross margins, despite ongoing operating losses. Expansion in key markets and new product launches signal potential future growth.
The life sciences company has been approved to trade on the OTCQB Venture Market in the US, aiming to increase its visibility and investor base in the country.
The life sciences company has signed a distribution agreement with a major weight management brand to sell its SlimBiome and WellBiome products under the partner's own branding.
The life sciences company has launched its appetite-reducing SlimBiome ingredient in a top-selling US weight loss supplement brand.
The life sciences company has issued options over new ordinary shares to a director.
The life sciences company reports strong growth in revenue, profit, and margins for the first half of 2025, driven by expansion into new markets and cost reductions.
The life sciences company has appointed Cairn Financial Advisers LLP as its new broker.
The life sciences company reported a 35% revenue increase but faced widening losses and margin pressure. Despite growth in key markets, economic uncertainties and supply chain challenges pose risks to future performance.
The healthcare company has announced the publication of a new study on its SlimBiome product in a prestigious scientific journal, providing further evidence of the product's efficacy.
The life sciences company has raised £750,000 through a discounted share placing to fund its expansion into the US market, but the significant discount raises concerns about investor appetite.